Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response.
作者信息
Wang Jin-Ming, Qiu Guo-Gao, Liu Zhi-Dong, Su Jia-Yong, Yang Da-Long, Deng Zhu-Jian, Li Zhi-Cheng, Zhong Jian-Hong
机构信息
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, China.
Department of General of Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530021, Guangxi, China.
出版信息
ILIVER. 2025 Feb 13;4(1):100145. doi: 10.1016/j.iliver.2025.100145. eCollection 2025 Mar.
Abstract
摘要
相似文献
1
Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response.不可切除肝细胞癌患者的治疗：完全缓解后的选择与管理
ILIVER. 2025 Feb 13;4(1):100145. doi: 10.1016/j.iliver.2025.100145. eCollection 2025 Mar.
2
External beam radiotherapy for unresectable hepatocellular carcinoma.不可切除肝细胞癌的外照射放疗
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.不同经动脉栓塞疗法单独或联合局部消融或辅助全身治疗对不可切除肝细胞癌的比较疗效：一项随机对照试验的网状Meta分析
PLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.0184597. eCollection 2017.
5
Efficacy analysis of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for initially unresectable hepatocellular carcinoma.肝动脉灌注化疗联合信迪利单抗和贝伐珠单抗治疗初治不可切除肝细胞癌的疗效分析
ILIVER. 2025 Apr 23;4(2):100163. doi: 10.1016/j.iliver.2025.100163. eCollection 2025 Jun.
6
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.系统治疗不可切除肝细胞癌的序贯治疗：随机临床试验的系统评价和贝叶斯网络荟萃分析。
Crit Rev Oncol Hematol. 2024 Dec;204:104522. doi: 10.1016/j.critrevonc.2024.104522. Epub 2024 Sep 26.
7
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.免疫治疗或靶向治疗作为不可切除肝细胞癌的一线策略：一项网络荟萃分析和成本效益分析。
Front Immunol. 2023 Jan 11;13:1103055. doi: 10.3389/fimmu.2022.1103055. eCollection 2022.
8
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.在高肿瘤负荷的不可切除肝细胞癌中，乐伐替尼和替雷利珠单抗对比阿替利珠单抗和贝伐单抗联合经动脉化疗栓塞性肝动脉灌注化疗：一项多中心回顾性队列研究
Cancer Immunol Immunother. 2025 Feb 1;74(3):88. doi: 10.1007/s00262-025-03942-3.
9
Tamoxifen for adults with hepatocellular carcinoma.他莫昔芬治疗肝细胞癌成人患者。
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.
10
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的系统评价与Meta分析
BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0.
本文引用的文献
1
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.多中心回顾性GUIDANCE001研究：比较经动脉化疗栓塞联合或不联合酪氨酸激酶和免疫检查点抑制剂作为转化治疗手段治疗不可切除肝细胞癌的疗效——中期或晚期而非早期阶段存在生存获益
Hepatology. 2025 Aug 1;82(2):357-369. doi: 10.1097/HEP.0000000000001229. Epub 2025 Jan 15.
2
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.对基于免疫疗法的全身治疗获得完全缓解的肝细胞癌患者的结局与管理
Hepatology. 2025 Jun 1;81(6):1714-1727. doi: 10.1097/HEP.0000000000001163. Epub 2024 Nov 21.
3
Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era.辅助治疗肝细胞癌：新时代的困境。
World J Gastroenterol. 2024 Feb 28;30(8):806-810. doi: 10.3748/wjg.v30.i8.806.
4
Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study.影像学完全缓解后转换治疗初不可切除的肝细胞癌患者的观察等待策略与切除术比较：倾向评分匹配的对比研究。
Int J Surg. 2024 May 1;110(5):2545-2555. doi: 10.1097/JS9.0000000000001155.
5
Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study.经肝动脉化疗栓塞术完全缓解后行肝切除术治疗中期肝细胞癌的生存获益：一项回顾性、多中心队列研究。
Int J Surg. 2024 Feb 1;110(2):1019-1027. doi: 10.1097/JS9.0000000000000942.
Zotero 插件